search
Back to results

The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial

Primary Purpose

Pressure Ulcer

Status
Completed
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Sponsored by
Changi General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pressure Ulcer focused on measuring Pressure Ulcer Wound, Specialized Amino Acid Mixture

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with pressure ulcers stage II, III or IV, non-healing admitted to Changi General Hospital for > 2 weeks
  • Patients who are able to attend outpatient follow-up appointments for dietary and wound review

Exclusion Criteria:

  • Age < 21 years old
  • Poorly controlled Diabetic Patients (HbA1c >7.0%)
  • Patients on Total Parenteral Nutrition
  • Patients in MICU/ SICU/ Medically Unstable/ Palliative Care
  • Patients with severe Sepsis
  • Length of stay < 2 weeks
  • Patients who require fluid restriction < 1L/d
  • Patients on any other wound healing supplements (e.g. Zinc, Vitamin A and Vitamin C)
  • Patients with lower extremity ulcers with untreated peripheral vascular disease
  • Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue
  • Patients unable to attend outpatient follow-up appointments
  • Patients who cannot tolerate oral intake > 70% EER and/or Fluid intake 30ml/kg BW
  • Patients who require protein restriction
  • Patients who are unable to give consent (absence of next-of-kin)

Sites / Locations

  • Changi General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Abound

Placebo

Arm Description

Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)

Placebo comparator that contains none of the active ingredients

Outcomes

Primary Outcome Measures

% Viable Tissue
-Percentage viable tissue after 2 weeks The estimated change in proportion of viable and non-viable tissue was determined using area derived from planimetry via acetate tracings. The description of viable tissue was taken to mean granulating (red) or epithelising (pink) tissue, and non-viable tissue were taken as necrotic (black) or sloughy (green or yellow) tissue.
% Wound Area Week 1
Percentage change in wound area after week 1
% Wound Area Week 2
Percentage change in wound area after week 2

Secondary Outcome Measures

Full Information

First Posted
March 18, 2010
Last Updated
June 14, 2013
Sponsor
Changi General Hospital
Collaborators
Abbott
search

1. Study Identification

Unique Protocol Identification Number
NCT01090076
Brief Title
The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial
Official Title
The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates-A Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
September 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Changi General Hospital
Collaborators
Abbott

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This research aims to address the gap in the studies done and test the effects of a commercial mixture of 7 g of Arginine, 7 g Glutamine and 1.2 g HMB* twice a day on hard to heal pressure ulcers in an Asian patient cohort in an acute healthcare setting.
Detailed Description
Pressure ulcers are defined as areas of localised damage to the skin, muscle or underlying tissue, caused by shear, friction or unrelieved pressure, usually over bony prominences. They are associated with many health conditions that cause prolonged bed rest, immobility, inactivity or poor sensation and can significantly contribute to morbidity and mortality, particularly in the aged population. International prevalence rates range widely from 4.6%- 83.6% due to methodological differences and classification systems. In Singapore, a study on the prevalence of pressure ulcers in 3 hospitals revealed a prevalence of 9% to 14%. Pressure ulcers often fail to heal in a timely and orderly manner, resulting in a chronic non-healing wound. Many intrinsic and extrinsic factors have been identified that can disrupt the wound healing processes of haemostasis, inflammation, proliferation, angiogenesis and remodelling. One of the factors gaining more interest for its impact on wound healing processes is nutritional status. Arginine is a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed during critical illness and severe trauma. There have been numerous research studies focusing on using arginine to enhance wound healing and pressure ulcer prevention. It is required for promotion of nitrogen balance, cell proliferation, T lymphocyte function and collagen accumulation. It also changes into nitric oxide, which is known for its vasodilatory and angiogenic properties. Glutamine is conditionally essential amino acid because it can be manufactured in the body, but under extreme physical stress the demand for glutamine exceeds the body's ability to make it. Adequate amounts of glutamine are generally obtained through diet alone because the body is also able to make glutamine on its own. Certain medical conditions, including injuries, surgery, infections, and prolonged stress, can deplete glutamine levels. Since glutamine plays a key role in the immune system, a deficiency in this nutrient can significantly slow the healing process. Beta-hydroxy-Beta methylbutyrate (HMB) is a metabolite of leucine, an essential amino acid. HMB supplementation was associated with increased muscle mass accretion. HMB appears to assert its effect via inhibiting muscle proteolysis and modulating protein turnover. Recently, arginine has been found to accelerate wound healing in combination with HMB and glutamine. It was shown that healthy subjects who are supplemented orally with arginine had a significant rise in plasma arginine and ornithine levels that led to enhanced rate of collagen synthesis. In another recent study, a HMB/Arginine/Lysine mixture increased protein turnover in elderly patients over a year long period. However, there is no known randomised controlled trial done on patients with chronic hard to heal wounds in acute healthcare settings. AIM To compare pressure ulcer healing rates in patients supplemented with a commercial HMB/Arginine/Lysine mixture (Abound) and standard high protein, high energy iso-nitrogenous medical nutritional supplements versus patients supplemented with only standard high protein, high energy iso-nitrogenous medical nutritional supplements. OUTCOME INDICATORS Percentage change in wound size (length, depth, area) Percentage change in proportion of viable wound tissue (Refer to wound data collection for details) The study will take on a comparative, randomised controlled trial design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcer
Keywords
Pressure Ulcer Wound, Specialized Amino Acid Mixture

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Abound
Arm Type
Experimental
Arm Description
Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo comparator that contains none of the active ingredients
Intervention Type
Dietary Supplement
Intervention Name(s)
Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Intervention Description
Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
Primary Outcome Measure Information:
Title
% Viable Tissue
Description
-Percentage viable tissue after 2 weeks The estimated change in proportion of viable and non-viable tissue was determined using area derived from planimetry via acetate tracings. The description of viable tissue was taken to mean granulating (red) or epithelising (pink) tissue, and non-viable tissue were taken as necrotic (black) or sloughy (green or yellow) tissue.
Time Frame
weeks 1 to 2
Title
% Wound Area Week 1
Description
Percentage change in wound area after week 1
Time Frame
week 0 to 1
Title
% Wound Area Week 2
Description
Percentage change in wound area after week 2
Time Frame
Weeks 1 to 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with pressure ulcers stage II, III or IV, non-healing admitted to Changi General Hospital for > 2 weeks Patients who are able to attend outpatient follow-up appointments for dietary and wound review Exclusion Criteria: Age < 21 years old Poorly controlled Diabetic Patients (HbA1c >7.0%) Patients on Total Parenteral Nutrition Patients in MICU/ SICU/ Medically Unstable/ Palliative Care Patients with severe Sepsis Length of stay < 2 weeks Patients who require fluid restriction < 1L/d Patients on any other wound healing supplements (e.g. Zinc, Vitamin A and Vitamin C) Patients with lower extremity ulcers with untreated peripheral vascular disease Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue Patients unable to attend outpatient follow-up appointments Patients who cannot tolerate oral intake > 70% EER and/or Fluid intake 30ml/kg BW Patients who require protein restriction Patients who are unable to give consent (absence of next-of-kin)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alvin Wong
Organizational Affiliation
Changi General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Changi General Hospital
City
Singapore
ZIP/Postal Code
529889
Country
Singapore

12. IPD Sharing Statement

Citations:
PubMed Identifier
19164608
Citation
Baier S, Johannsen D, Abumrad N, Rathmacher JA, Nissen S, Flakoll P. Year-long changes in protein metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-methylbutyrate (HMB), L-arginine, and L-lysine. JPEN J Parenter Enteral Nutr. 2009 Jan-Feb;33(1):71-82. doi: 10.1177/0148607108322403.
Results Reference
background
PubMed Identifier
15665304
Citation
Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by beta-hydroxy-beta-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005 Jan 1;65(1):277-83.
Results Reference
background
PubMed Identifier
17609254
Citation
Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E923-31. doi: 10.1152/ajpendo.00314.2007. Epub 2007 Jul 3.
Results Reference
background
PubMed Identifier
16207646
Citation
Stechmiller JK, Childress B, Cowan L. Arginine supplementation and wound healing. Nutr Clin Pract. 2005 Feb;20(1):52-61. doi: 10.1177/011542650502000152.
Results Reference
background
PubMed Identifier
11431045
Citation
Benati G, Delvecchio S, Cilla D, Pedone V. Impact on pressure ulcer healing of an arginine-enriched nutritional solution in patients with severe cognitive impairment. Arch Gerontol Geriatr Suppl. 2001;7:43-7. doi: 10.1016/s0167-4943(01)00120-0. No abstract available.
Results Reference
background
PubMed Identifier
16297506
Citation
Desneves KJ, Todorovic BE, Cassar A, Crowe TC. Treatment with supplementary arginine, vitamin C and zinc in patients with pressure ulcers: a randomised controlled trial. Clin Nutr. 2005 Dec;24(6):979-87. doi: 10.1016/j.clnu.2005.06.011. Epub 2005 Nov 15.
Results Reference
background
PubMed Identifier
24810310
Citation
Wong A, Chew A, Wang CM, Ong L, Zhang SH, Young S. The use of a specialised amino acid mixture for pressure ulcers: a placebo-controlled trial. J Wound Care. 2014 May;23(5):259-60, 262-4, 266-9. doi: 10.12968/jowc.2014.23.5.259.
Results Reference
derived

Learn more about this trial

The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial

We'll reach out to this number within 24 hrs